 
| In ZINC since | Heavy atoms | Benign functionality | 
|---|---|---|
| October 6th, 2004 | 40 | No | 
Popular Name: Lapatinib Lapatinib
Find On: PubMed — Wikipedia — Google
CAS Numbers: 231277-92-2 , 388082-78-8 , [231277-92-2]
231277-92-2; D08108; Lapatinib (INN)
388082-78-8; D04024; Lapatinib ditosylate (USAN); Lapatinib tosilate hydrate (JAN); Tykerb (TN)
FMM;GW 572016;GW572016;Lapatinib ditosylate;Lapatinib tosilate hydrate
Lapatinib (INN); Lapatinib Ditosylate (FDA
LAPATINIB DITOSYLATE MONOHYDRATE
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL | 
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 6.16 | -3.53 | -72.53 | 3 | 8 | 1 | 110 | 582.077 | 11 | ↓ | 
| Note Type | Comments | Provided By | 
|---|---|---|
| ALOGPS_SOLUBILITY | 2.23e-02 g/l | DrugBank-approved | 
| Indications | breast cancer | KeyOrganics Bioactives | 
| Patent Database Links | EP1977765; EP1982718; EP1988164; US2005276812; US2007248604; US2007259031; US2008255087; WO2006097323; WO2007096393; WO2007096395; WO2007100385; WO2007106432; WO2007113268; WO2007113269; WO2007113270; WO2007128827; WO2007128829; WO2008128171; WO2008156614 | ChEBI | 
| UniProt Database Links | ERBB4_HUMAN | ChEBI | 
| Reactome Database Links | REACT_115609 | ChEBI | 
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type | 
|---|---|---|---|---|---|
| EGFR-1-E | Epidermal Growth Factor Receptor ErbB1 (cluster #1 Of 4), Eukaryotic | Eukaryotes | 9 | 0.28 | Binding ≤ 10μM | 
| ERBB2-2-E | Receptor Protein-tyrosine Kinase ErbB-2 (cluster #2 Of 3), Eukaryotic | Eukaryotes | 9 | 0.28 | Binding ≤ 10μM | 
| PGFRB-1-E | Platelet-derived Growth Factor Receptor Beta (cluster #1 Of 1), Eukaryotic | Eukaryotes | 8500 | 0.18 | Binding ≤ 10μM | 
| RIPK2-1-E | Serine/threonine-protein Kinase RIPK2 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 3600 | 0.19 | Binding ≤ 10μM | 
| SLK-1-E | Serine/threonine-protein Kinase 2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 9300 | 0.18 | Binding ≤ 10μM | 
| STK10-1-E | Serine/threonine-protein Kinase 10 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 4400 | 0.19 | Binding ≤ 10μM | 
| TBA1A-1-E | Tubulin Alpha-3 Chain (cluster #1 Of 3), Eukaryotic | Eukaryotes | 54 | 0.25 | Binding ≤ 10μM | 
| Z103205-1-O | A431 (cluster #1 Of 4), Other | Other | 970 | 0.21 | Functional ≤ 10μM | 
| Z80046-1-O | BT-474 (Breast Ductal Carcinoma Cells) (cluster #1 Of 1), Other | Other | 80 | 0.25 | Functional ≤ 10μM | 
| Z80224-1-O | MCF7 (Breast Carcinoma Cells) (cluster #1 Of 14), Other | Other | 6600 | 0.18 | Functional ≤ 10μM | 
| Z80300-1-O | N87 (Gastric Carcinoma Cells) (cluster #1 Of 1), Other | Other | 80 | 0.25 | Functional ≤ 10μM | 
| Z80475-3-O | SK-BR-3 (Breast Adenocarcinoma) (cluster #3 Of 3), Other | Other | 4350 | 0.19 | Functional ≤ 10μM | 
| Z80493-1-O | SK-OV-3 (Ovarian Carcinoma Cells) (cluster #1 Of 6), Other | Other | 3 | 0.30 | Functional ≤ 10μM | 
| Z80682-1-O | A549 (Lung Carcinoma Cells) (cluster #1 Of 11), Other | Other | 8500 | 0.18 | Functional ≤ 10μM | 
| Z80954-1-O | HFF (Foreskin Fibroblasts) (cluster #1 Of 4), Other | Other | 9900 | 0.18 | Functional ≤ 10μM | 
| Z80961-1-O | HN5 (Squamous Cell Carcinoma) (cluster #1 Of 1), Other | Other | 25 | 0.27 | Functional ≤ 10μM | 
| Z81020-7-O | HepG2 (Hepatoblastoma Cells) (cluster #7 Of 8), Other | Other | 6270 | 0.18 | Functional ≤ 10μM | 
| Z81247-1-O | HeLa (Cervical Adenocarcinoma Cells) (cluster #1 Of 9), Other | Other | 5900 | 0.18 | Functional ≤ 10μM | 
| Z81252-3-O | MDA-MB-231 (Breast Adenocarcinoma Cells) (cluster #3 Of 11), Other | Other | 5400 | 0.18 | Functional ≤ 10μM | 
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type | 
|---|---|---|---|---|---|
| EGFR_HUMAN | P00533 | Epidermal Growth Factor Receptor ErbB1, Human | 10 | 0.28 | Binding ≤ 1μM | 
| ERBB2_HUMAN | P04626 | Receptor Protein-tyrosine Kinase ErbB-2, Human | 124 | 0.24 | Binding ≤ 1μM | 
| TBA1A_RAT | P68370 | Tubulin Alpha-1 Chain, Rat | 54 | 0.25 | Binding ≤ 1μM | 
| EGFR_HUMAN | P00533 | Epidermal Growth Factor Receptor ErbB1, Human | 10 | 0.28 | Binding ≤ 10μM | 
| PGFRB_HUMAN | P09619 | Platelet-derived Growth Factor Receptor Beta, Human | 8500 | 0.18 | Binding ≤ 10μM | 
| ERBB2_HUMAN | P04626 | Receptor Protein-tyrosine Kinase ErbB-2, Human | 124 | 0.24 | Binding ≤ 10μM | 
| STK10_HUMAN | O94804 | Serine/threonine-protein Kinase 10, Human | 2600 | 0.20 | Binding ≤ 10μM | 
| SLK_HUMAN | Q9H2G2 | Serine/threonine-protein Kinase 2, Human | 9300 | 0.18 | Binding ≤ 10μM | 
| RIPK2_HUMAN | O43353 | Serine/threonine-protein Kinase RIPK2, Human | 3600 | 0.19 | Binding ≤ 10μM | 
| TBA1A_RAT | P68370 | Tubulin Alpha-1 Chain, Rat | 54 | 0.25 | Binding ≤ 10μM | 
| Z103205 | Z103205 | A431 | 104 | 0.24 | Functional ≤ 10μM | 
| Z80682 | Z80682 | A549 (Lung Carcinoma Cells) | 8500 | 0.18 | Functional ≤ 10μM | 
| Z80046 | Z80046 | BT-474 (Breast Ductal Carcinoma Cells) | 25 | 0.27 | Functional ≤ 10μM | 
| Z81247 | Z81247 | HeLa (Cervical Adenocarcinoma Cells) | 5900 | 0.18 | Functional ≤ 10μM | 
| Z81020 | Z81020 | HepG2 (Hepatoblastoma Cells) | 6270 | 0.18 | Functional ≤ 10μM | 
| Z80954 | Z80954 | HFF (Foreskin Fibroblasts) | 9900 | 0.18 | Functional ≤ 10μM | 
| Z80961 | Z80961 | HN5 (Squamous Cell Carcinoma) | 120 | 0.24 | Functional ≤ 10μM | 
| Z80224 | Z80224 | MCF7 (Breast Carcinoma Cells) | 6600 | 0.18 | Functional ≤ 10μM | 
| Z81252 | Z81252 | MDA-MB-231 (Breast Adenocarcinoma Cells) | 5400 | 0.18 | Functional ≤ 10μM | 
| Z80300 | Z80300 | N87 (Gastric Carcinoma Cells) | 80 | 0.25 | Functional ≤ 10μM | 
| Z80475 | Z80475 | SK-BR-3 (Breast Adenocarcinoma) | 40 | 0.26 | Functional ≤ 10μM | 
| Z80493 | Z80493 | SK-OV-3 (Ovarian Carcinoma Cells) | 3 | 0.30 | Functional ≤ 10μM | 
| Description | Species | 
|---|---|
| Signaling by constitutively active EGFR | 
| Description | Species | 
|---|---|
| activated TAK1 mediates p38 MAPK activation | |
| Constitutive PI3K/AKT Signaling in Cancer | |
| Downregulation of ERBB2:ERBB3 signaling | |
| Downstream signal transduction | |
| Downstream TCR signaling | |
| EGFR downregulation | |
| EGFR interacts with phospholipase C-gamma | |
| EGFR Transactivation by Gastrin | |
| Formation of tubulin folding intermediates by CCT/TriC | |
| GAB1 signalosome | |
| Gap junction assembly | |
| GRB2 events in EGFR signaling | |
| GRB2 events in ERBB2 signaling | |
| GRB7 events in ERBB2 signaling | |
| Interleukin-1 signaling | |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human | |
| Kinesins | |
| Loss of Nlp from mitotic centrosomes | |
| Loss of proteins required for interphase microtubule organization from the ce | |
| MHC class II antigen presentation | |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | |
| Mitotic Prometaphase | |
| NOD1/2 Signaling Pathway | |
| p75NTR recruits signalling complexes | |
| PI3K events in ERBB2 signaling | |
| PIP3 activates AKT signaling | |
| PLCG1 events in ERBB2 signaling | |
| Post-chaperonin tubulin folding pathway | |
| Prefoldin mediated transfer of substrate to CCT/TriC | |
| Recruitment of mitotic centrosome proteins and complexes | |
| Recruitment of NuMA to mitotic centrosomes | |
| Recycling pathway of L1 | |
| Regulation of PLK1 Activity at G2/M Transition | |
| Resolution of Sister Chromatid Cohesion | |
| Sema4D induced cell migration and growth-cone collapse | |
| Separation of Sister Chromatids | |
| SHC1 events in EGFR signaling | |
| SHC1 events in ERBB2 signaling | |
| Signal transduction by L1 | |
| Signaling by constitutively active EGFR | |
| Signaling by EGFR | |
| Signaling by ERBB2 | |
| Signaling by ERBB4 | |
| Signaling by PDGF | |
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |
| Translocation of GLUT4 to the plasma membrane | 
No pre-computed analogs available. Try a structural similarity search.